Inhibition of a vesicular stomatitis virus mutant by rifampin.
Rifampin reversibly inhibits the intracellular replication of a VSV mutant, whereas a revertant variant selected from this viral population, as well as the wild strain, are not affected by this drug. Rifampin inhibits transcriptase activity of the sensitive mutant only and, consequently, total viral RNA synthesis decreases significantly in the cells.
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D002642:Chick Embryo; D012321:DNA-Directed RNA Polymerases / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005347:Fibroblasts; D006150:Guanine Nucleotides; D000882:Haplorhini; D066298:In Vitro Techniques; D007668:Kidney; D007739:L Cells; D009154:Mutation; D012367:RNA, Viral / Q000096:biosynthesis; D012293:Rifampin / Q000494:pharmacology*; D014316:Tritium; D014529:Uridine; D014721:Vesicular stomatitis Indiana virus / Q000187:drug effects / Q000201:enzymology / Q000254:growth & development*; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D006150:Guanine Nucleotides; D012367:RNA, Viral; D014316:Tritium; D012321:DNA-Directed RNA Polymerases; D012293:Rifampin; D014529:Uridine